市場調査レポート

商品コード

1715307

前立腺肥大症治療市場：治療タイプ、製品タイプ、エンドユーザー別-2025-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User - Global Forecast 2025-2030

出版日: 2025年04月01日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日

カスタマイズ可能

適宜更新あり

価格

PDF, Excel & 1 Year Online Access (Single User License)

USD 3,939 578,323円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

PDF, Excel & 1 Year Online Access (2-5 User License)

USD 4,249 623,838円

レポートPDF及びExcelを5名までご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

PDF, Excel & 1 Year Online Access (Site License)

USD 5,759 845,536円

レポートPDF及びExcelを、同じ地理上の位置に所在する事業所内に所属の全ての方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

PDF, Excel & 1 Year Online Access (Enterprise User License)

USD 6,969 1,023,188円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。オンラインプラットフォーム上で1年間、何度でもレポートをダウンロードする事が可能な上、定期的に更新される情報にアクセスする事が可能です（更新は年3-4回程度）。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

前立腺肥大症治療市場の2024年の市場規模は14億2,000万米ドルで、2025年には15億米ドル、CAGR 5.91%で成長し、2030年には20億1,000万米ドルに達すると予測されています。

主な市場の統計
基準年 2024	14億2,000万米ドル
推定年 2025	15億米ドル
予測年 2030	20億1,000万米ドル
CAGR（%）	5.91%

前立腺肥大症（BPH）は、男性人口の大部分に影響を及ぼす重大な健康課題であり、広範な調査、革新的な治療法、進化する臨床実践につながっています。近年、医療技術の進歩と患者の意識の向上により、前立腺肥大症の診断と管理におけるパラダイムシフトが起こっています。ヘルスケア利害関係者が有効性、患者の快適性、費用対効果のバランスがとれた解決策を求めて努力する中、市場は急速な進化を遂げています。歴史的に伝統的な外科的介入によって管理されてきたBPHの治療は、現在では薬理学的解決策から最先端の低侵襲手技まで、さまざまな治療法を包含しています。この包括的な分析では、臨床的進歩と市場動向の両方に焦点を当て、現在の治療状況の多面的なダイナミクスを探ります。根本的な促進要因と阻害要因を検証することで、本レポートは、治療イノベーションと患者中心のアプローチがいかに業界を再形成しつつあるかを明確に理解することを目的としています。以下のセクションでは、変革的なシフト、競合考察、地域動向、競合ダイナミクスを掘り下げ、業界リーダーが十分な情報を得た上で戦略的な意思決定を行えるよう、実用的な提言を提示します。

治療モダリティと市場力学を再定義する変革的シフト

近年、BPH治療の状況は、臨床と市場力学の両方を再定義する変革的なシフトを目の当たりにしています。医学は従来の方法を超えて急速に進歩し、患者の安全性と治療成果の向上を最優先とする技術革新を受け入れています。侵襲的な外科手術に依存してきた従来の方法は、回復時間を短縮し、付随的な組織損傷を最小限に抑える無数の低侵襲治療へと徐々に移行しつつあります。研究者と臨床医は、精度と的を絞った有効性を提供する技術を採用し、技術革新が鍵となる競合市場環境を醸成しています。

こうしたシフトは、医療用画像の進歩、生体材料の改良、手技中のリアルタイム・モニタリング・システムの統合など、複数の要因に影響されています。さらに、患者の人口動態の変化と外来患者サービスの需要の増加が、早期回復と入院期間の短縮をサポートする技術の採用を後押ししています。価値観に基づく医療が重視されるようになるにつれ、市場は新規治療法の研究開発および規制当局による支援に積極的に取り組んでいます。結局のところ、こうした動向は治療効果の限界を押し広げると同時に、患者ケア全体を最適化し、技術革新と医療規範の進化が複雑に絡み合う中で市場を持続的成長へと導いています。

市場浸透を促進する包括的なセグメンテーションの洞察

BPH治療の市場セグメンテーションは、明確な市場動向を明らかにし、投資の機が熟した分野を特定する上で重要な役割を果たします。治療タイプ別に市場を分析すると、薬物療法、低侵襲治療、外科治療で大きな違いが見られます。薬物療法は、5αリダクターゼ阻害薬とα遮断薬にさらに区別され、手術に代わる非侵襲的な選択肢を提供し続けています。前立腺動脈塞栓術や水蒸気療法などの低侵襲療法は、有効性と回復期間の短縮のバランスがとれた有望な選択肢として登場してきました。対照的に、外科的治療は依然として不可欠であり、レーザー手術、前立腺尿道リフト、経尿道的前立腺切開術、経尿道的前立腺切除術などの選択肢が、進行した症例に決定的な解決策を提供しています。

さらに、製品タイプに基づくセグメンテーションは、この市場を牽引する幅広い重要な要素に光を当てています。カテーテル、電極、インプラント、前立腺ステント、切除鏡、泌尿器科用レーザーなどの医療器具における技術革新は、手技の成果と患者の安全性を大幅に向上させています。エンドユーザーに基づくセグメンテーションでは、外来手術センター、診療所、病院でのさまざまな需要に見られるように、設定に応じたアプリケーションの重要性がさらに強調されています。これらのセグメンテーションを統合的に理解することで、利害関係者は、ダイナミックなBPH治療分野で戦略を調整し、新たな機会を活用するために必要な詳細な洞察を得ることができます。

市場力学
- 促進要因
  - 良性前立腺肥大症の発生率の上昇と診断の改善
  - 効果的な非外科的治療オプションに対する患者の意識と好みの高まり
  - 世界のヘルスケアインフラの拡大
- 抑制要因
  - 良性前立腺肥大症の症状に関する認識不足
- 機会
  - 良性前立腺肥大症の低侵襲治療における継続的な革新
  - ビッグデータ分析を活用して前立腺肥大症の診断と治療プロセスを強化する
- 課題
  - 良性前立腺肥大症治療における規制の複雑さ
市場セグメンテーション分析
- 治療の種類：薬物療法と外科的治療を組み合わせた前立腺肥大症治療への関心が高まっている
- エンドユーザー：外来手術センターにおける前立腺肥大症治療の使用増加
ポーターのファイブフォース分析
PESTEL分析
- 政治的
- 経済
- 社会
- 技術的
- 法律上
- 環境

第6章前立腺肥大症治療市場治療の種類別

医薬品
- 5α還元酵素阻害剤
- アルファ遮断薬
低侵襲治療
- 前立腺動脈塞栓術
- 水蒸気療法
外科的治療
- レーザー手術
- 前立腺尿道リフト
- 経尿道的前立腺切開術
- 経尿道的前立腺切除術

第7章前立腺肥大症治療市場：製品タイプ別

カテーテル
電極
インプラント
前立腺ステント
切除鏡
泌尿器科レーザー

第8章前立腺肥大症治療市場：エンドユーザー別

外来手術センター
クリニック
病院

第9章南北アメリカの前立腺肥大症治療市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第10章アジア太平洋地域の前立腺肥大症治療市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第11章欧州・中東・アフリカの前立腺肥大症治療市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第12章競合情勢

市場シェア分析, 2024
FPNVポジショニングマトリックス, 2024
競合シナリオ分析
戦略分析と提言

企業一覧

Abbott Laboratories
AbbVie Inc.
Asahi Kasei Corporation
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Boston Scientific Corporation
Cipla Ltd.
Dr. Reddy's Laboratories
Eli Lilly and Company
Endo International PLC
GlaxoSmithKline plc
Hikma Pharmaceuticals PLC
Lumenis Ltd.
Lupin Pharmaceuticals
Medtronic PLC
Merck & Co., Inc.
Merit Medical Systems
Mylan N.V.
Olympus Corporation
Pfizer, Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Teleflex Incorporated
Teva Pharmaceutical Industries Ltd.

図表

LIST OF FIGURES

FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 15. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 17. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 23. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 54. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 55. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 86. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 87. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 88. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 92. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 94. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 196. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 197. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 219. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 221. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 225. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 226. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 227. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)

TABLE

Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 1.42 billion in 2024 and is projected to grow to USD 1.50 billion in 2025, with a CAGR of 5.91%, reaching USD 2.01 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.42 billion
Estimated Year [2025]	USD 1.50 billion
Forecast Year [2030]	USD 2.01 billion
CAGR (%)	5.91%

Benign Prostatic Hyperplasia (BPH) represents a significant health challenge that affects a large segment of the male population, leading to extensive research, innovative therapies, and evolving clinical practices. In recent years, advances in medical technology and increased patient awareness have driven a paradigm shift in the diagnosis and management of BPH. The market is witnessing rapid evolution as healthcare stakeholders strive for solutions that balance efficacy, patient comfort, and cost-effectiveness. Historically managed through traditional surgical interventions, the treatment of BPH now embraces a spectrum of therapies ranging from pharmacological solutions to state-of-the-art minimally invasive procedures. This comprehensive analysis explores the multifaceted dynamics of the current treatment landscape, focusing on both clinical advancements and market trends. By examining the underlying drivers and impediments, this report aims to provide a clear understanding of how treatment innovations and patient-centric approaches are reshaping the industry. The following sections delve deeper into transformative shifts, segmentation insights, regional trends, and competitive dynamics, setting the stage for actionable recommendations to empower industry leaders in making informed strategic decisions.

Transformative Shifts Redefining Treatment Modalities and Market Dynamics

In recent years, the BPH treatment landscape has witnessed transformative shifts that are redefining both clinical practices and market dynamics. Medical science has rapidly progressed beyond conventional methods, embracing innovations that prioritize patient safety and enhanced therapeutic outcomes. The traditional reliance on invasive surgical procedures is gradually giving way to a myriad of minimally invasive treatments that reduce recovery time and minimize collateral tissue damage. Researchers and clinicians have embraced technologies that offer precision and targeted efficacy, thereby fostering a competitive market environment where innovation is key.

These shifts have been influenced by multiple factors including advancements in medical imaging, improved biomaterials, and the integration of real-time monitoring systems during procedures. Additionally, evolving patient demographics and increasing demand for outpatient services have driven the adoption of technologies that support quicker recovery and reduced hospital stays. As the emphasis on value-based care intensifies, the market is witnessing a strong commitment to research, development, and regulatory support for novel treatments. Ultimately, these trends are pushing boundaries in treatment efficacy while simultaneously optimizing overall patient care, positioning the market for sustained growth amidst a complex interplay of technological innovation and evolving healthcare norms.

Comprehensive Segmentation Insights Driving Market Penetration

The market segmentation of BPH treatments plays a critical role in illuminating distinct market trends and identifying areas ripe for investment. Analyzing the market based on treatment type, significant variation is observed across medications, minimally invasive therapies, and surgical treatments. Medications, which are further differentiated into 5-Alpha-Reductase Inhibitors and Alpha Blockers, continue to provide a non-invasive alternative to surgery. Minimally invasive therapies, including procedures such as Prostate Artery Embolization and Water Vapour Therapy, have emerged as promising options that strike a balance between efficacy and a reduced recovery period. In contrast, surgical treatments remain essential, with options like Laser Surgery, Prostatic Urethral Lift, Transurethral Incision Of The Prostate, and Transurethral Resection Of The Prostate offering definitive solutions in advanced cases.

Furthermore, segmentation based on product type has shed light on a wide range of critical components driving this market. Innovations in medical instruments such as Catheters, Electrodes, Implants, Prostatic Stents, Resectoscopes, and Urology Laser have significantly enhanced procedural outcomes and patient safety. Segmentation based on the end user further emphasizes the importance of setting-specific applications, with varying demands observed in Ambulatory Surgical Centers, Clinics, and Hospitals. An integrated understanding of these segmentations provides stakeholders with the granular insights needed to tailor strategies and capitalize on emerging opportunities within the dynamic BPH treatment arena.

Based on Treatment Type, market is studied across Medications, Minimally Invasive Therapies, and Surgical Treatments. The Medications is further studied across 5-Alpha-Reductase Inhibitors and Alpha Blockers. The Minimally Invasive Therapies is further studied across Prostate Artery Embolization and Water Vapour Therapy. The Surgical Treatments is further studied across Laser Surgery, Prostatic Urethral Lift, Transurethral Incision Of The Prostate, and Transurethral Resection Of The Prostate.

Based on Product Type, market is studied across Catheters, Electrodes, Implants, Prostatic Stents, Resectoscopes, and Urology Laser.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.

Regional Trends and Emerging Markets in a Dynamic Global Environment

The regional analysis of the BPH treatment market reveals a landscape where differing economic, demographic, and regulatory factors play pivotal roles in shaping growth trajectories. In the Americas, robust healthcare infrastructure and strong investments in medical technology foster a competitive environment marked by rapid adoption of innovative therapies. Market dynamics in this region reflect a high degree of clinical research, regulatory support, and a service-oriented approach to patient care.

Similarly, the Europe, Middle East & Africa region showcases a diverse spectrum of healthcare systems where policy reforms and investment in translational medicine are accelerating the implementation of both conventional and novel treatment modalities. Simultaneously, cultural nuances and varying degrees of access to advanced technology influence treatment choices and outcomes. The Asia-Pacific region offers a contrasting picture, characterized by burgeoning middle-class populations, rising incidence of BPH, and a significant push towards modernization of its healthcare delivery systems. Despite challenges related to infrastructure and regulatory harmonization, rapid urbanization and increased healthcare spending in this region are setting the stage for considerable market expansion. Together, these regional insights underscore the importance of tailored strategies that address local challenges while leveraging global innovation trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Strategic Insights from Leading Industry Innovators

A detailed review of the competitive environment in the BPH treatment market reveals a highly dynamic landscape where both multinational giants and specialized regional players are actively contributing to industry innovation. Leading companies such as Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, and Astellas Pharma Inc. are at the forefront of research and development, bringing forward new therapies and refining existing treatment protocols. Global players like Bayer AG, Boehringer Ingelheim GmbH, Boston Scientific Corporation, and Cipla Ltd. have also significantly impacted market penetration through strategic collaborations and extensive clinical trials.

Other noteworthy companies include Dr. Reddy's Laboratories, Eli Lilly and Company, Endo International PLC, and GlaxoSmithKline plc, each of which has leveraged its expertise to enhance the overall treatment spectrum. This competitive set is further bolstered by innovators such as Hikma Pharmaceuticals PLC, Lumenis Ltd., Lupin Pharmaceuticals, Medtronic PLC, and Merck & Co., Inc., whose investments have led to improvements in both product design and procedural approaches. Additional industry leaders including Merit Medical Systems, Mylan N.V., Olympus Corporation, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd. contribute to a competitive landscape that is defined by relentless innovation, strategic market positioning, and an unwavering commitment to improving patient outcomes across the globe.

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Cipla Ltd., Dr. Reddy's Laboratories, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lumenis Ltd., Lupin Pharmaceuticals, Medtronic PLC, Merck & Co., Inc., Merit Medical Systems, Mylan N.V., Olympus Corporation, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Strategic Market Leadership

To navigate the complex dynamics of the BPH treatment market, industry leaders must adopt a forward-thinking strategy that capitalizes on current trends while anticipating future challenges. It is imperative to invest in research and development to continuously refine minimally invasive treatments and integrate state-of-the-art technologies that enhance procedural accuracy and patient safety. Fostering partnerships between clinical research entities, technology developers, and regulatory bodies can accelerate the translation of innovative therapies from the laboratory to the clinical setting.

Leaders should also consider a diversified portfolio approach that encompasses various treatment modalities and product types to mitigate risks and capture emerging opportunities. Emphasis on enhancing the patient journey through improved diagnostics, personalized treatment protocols, and streamlined care pathways is vital. Moreover, targeted regional strategies that address local healthcare needs and economic environments are essential to capture untapped market segments and drive sustainable growth.

Conclusion: A Forward Path in BPH Treatment Innovation and Market Expansion

The evolving dynamics of the BPH treatment market underscore significant progress in medical innovation and a shift toward more patient-focused therapeutic solutions. Advances in minimally invasive procedures, enhanced product technologies, and improved diagnostic methodologies collectively paint a picture of a market poised for substantial growth. The convergence of clinical excellence with strategic market segmentation has enabled stakeholders to better understand patient needs and tailor interventions accordingly. This, combined with robust regional growth patterns and a competitive environment driven by industry leaders, creates an ecosystem where innovation and patient care are paramount.

In summary, the market stands at an inflection point where technological advancements and strategic collaborations can forge a future marked by improved outcomes and increased accessibility to cutting-edge treatments. With clear insights and actionable strategies in place, stakeholders are well-equipped to navigate the complexities of the competitive landscape and drive meaningful value in the BPH treatment space.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidence and improved diagnosis of benign prostatic hyperplasia conditions
  - 5.1.1.2. Growing patient awareness and preference for effective non-surgical treatment options
  - 5.1.1.3. Expansion of healthcare infrastructure globally
- 5.1.2. Restraints
  - 5.1.2.1. Lack of awareness about benign prostatic hyperplasia symptoms
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing innovations in minimally invasive treatments for benign prostatic hyperplasia
  - 5.1.3.2. Leveraging big data analytics to enhance benign prostatic hyperplasia diagnostic and treatment processes
- 5.1.4. Challenges
  - 5.1.4.1. Regulatory complexities for benign prostatic hyperplasia treatments
5.2. Market Segmentation Analysis
- 5.2.1. Treatment Type: Growing preference for benign prostatic hyperplasia treatment using medication and surgical treatment
- 5.2.2. End User: Increasing use of benign prostatic hyperplasia treatment in ambulatory surgical centers
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

6.1. Introduction
6.2. Medications
- 6.2.1. 5-Alpha-Reductase Inhibitors
- 6.2.2. Alpha Blockers
6.3. Minimally Invasive Therapies
- 6.3.1. Prostate Artery Embolization
- 6.3.2. Water Vapour Therapy
6.4. Surgical Treatments
- 6.4.1. Laser Surgery
- 6.4.2. Prostatic Urethral Lift
- 6.4.3. Transurethral Incision Of The Prostate
- 6.4.4. Transurethral Resection Of The Prostate

7. Benign Prostatic Hyperplasia Treatment Market, by Product Type

7.1. Introduction
7.2. Catheters
7.3. Electrodes
7.4. Implants
7.5. Prostatic Stents
7.6. Resectoscopes
7.7. Urology Laser

8. Benign Prostatic Hyperplasia Treatment Market, by End User

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Hospitals

9. Americas Benign Prostatic Hyperplasia Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2024
12.2. FPNV Positioning Matrix, 2024
12.3. Competitive Scenario Analysis
- 12.3.1. Mount Sinai launches a new robotic system for treating an enlarged prostate.
- 12.3.2. Zenflow secures USD 24 million Series C to drive FDA pre-market approval and commercialization of Spring System
- 12.3.3. Rivermark Medical secures USD 30 million Series C investment for development of FloStent
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. AbbVie Inc.
3. Asahi Kasei Corporation
4. Astellas Pharma Inc.
5. Bayer AG
6. Boehringer Ingelheim GmbH
7. Boston Scientific Corporation
8. Cipla Ltd.
9. Dr. Reddy's Laboratories
10. Eli Lilly and Company
11. Endo International PLC
12. GlaxoSmithKline plc
13. Hikma Pharmaceuticals PLC
14. Lumenis Ltd.
15. Lupin Pharmaceuticals
16. Medtronic PLC
17. Merck & Co., Inc.
18. Merit Medical Systems
19. Mylan N.V.
20. Olympus Corporation
21. Pfizer, Inc.
22. Sanofi S.A.
23. Sun Pharmaceutical Industries Ltd.
24. Teleflex Incorporated
25. Teva Pharmaceutical Industries Ltd.

前立腺肥大症治療市場：治療タイプ、製品タイプ、エンドユーザー別-2025-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User - Global Forecast 2025-2030

目次

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章前立腺肥大症治療市場治療の種類別

第7章前立腺肥大症治療市場：製品タイプ別

第8章前立腺肥大症治療市場：エンドユーザー別

第9章南北アメリカの前立腺肥大症治療市場

第10章アジア太平洋地域の前立腺肥大症治療市場

第11章欧州・中東・アフリカの前立腺肥大症治療市場

第12章競合情勢

企業一覧

LIST OF FIGURES

LIST OF TABLES

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

7. Benign Prostatic Hyperplasia Treatment Market, by Product Type

8. Benign Prostatic Hyperplasia Treatment Market, by End User

9. Americas Benign Prostatic Hyperplasia Treatment Market

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

12. Competitive Landscape

Companies Mentioned

前立腺肥大症治療市場：治療タイプ、製品タイプ、エンドユーザー別-2025-2030年の世界予測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User - Global Forecast 2025-2030

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 前立腺肥大症治療市場治療の種類別

第7章 前立腺肥大症治療市場：製品タイプ別

第8章 前立腺肥大症治療市場：エンドユーザー別

第9章 南北アメリカの前立腺肥大症治療市場

第10章 アジア太平洋地域の前立腺肥大症治療市場

第11章 欧州・中東・アフリカの前立腺肥大症治療市場

第12章 競合情勢

企業一覧

LIST OF FIGURES

LIST OF TABLES

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

7. Benign Prostatic Hyperplasia Treatment Market, by Product Type

8. Benign Prostatic Hyperplasia Treatment Market, by End User

9. Americas Benign Prostatic Hyperplasia Treatment Market

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

12. Competitive Landscape

Companies Mentioned

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章前立腺肥大症治療市場治療の種類別

第7章前立腺肥大症治療市場：製品タイプ別

第8章前立腺肥大症治療市場：エンドユーザー別

第9章南北アメリカの前立腺肥大症治療市場

第10章アジア太平洋地域の前立腺肥大症治療市場

第11章欧州・中東・アフリカの前立腺肥大症治療市場

第12章競合情勢